Carbapenemase inhibitors: updates on developments in 2021.

No Thumbnail Available
Authors
Shaker, Waleed
Issue Date
2022-07-29
Journal
Type
Peer-Reviewed Publication
Review
Keywords
Carbapenemase inhibitors
Carbapenemase resistance
Pathogens
Journal Title
Journal of Clinical Medicine Research
Volume
14
Issue
7
Begin page
251
End page
259
Abstract
Carbapenem resistance, an emerging global health problem, compromises the treatment of infections caused by nosocomial pathogens. Preclinical and clinical trials demonstrate that a new generation of carbapenemases inhibitors, together with the recently approved avibactam, relebactam and vaborbactam, would address this resistance. Our review summarizes the latest developments related to carbapenemase inhibitors synthesized to date, as well as their spectrum of activity and their current stage of development. A particular focus will be on β-lactam/β-lactamase inhibitor combinations that could potentially be used to treat infections caused by carbapenemase-producer pathogens. These new combinations mark a critical step forward the fight against antimicrobial resistance.
Citation
Bou Zerdan M, Al Hassan S, Shaker W, El Hajjar R, Allam S, Bou Zerdan M, Naji A, Zeineddine N. Carbapenemase Inhibitors: Updates on Developments in 2021. J Clin Med Res. 2022 Jul;14(7):251-259. doi: 10.14740/jocmr4764. Epub 2022 Jul 29. PMID: 35974805; PMCID: PMC9365662.